USH3A Activators constitute a diverse array of chemical compounds with the specific capability to enhance the functional activity of USH3A through a variety of signaling pathways. Forskolin, Isoproterenol, and db-cAMP directly elevate cAMP levels within cells, leading to the activation of PKA. This kinase is known to phosphorylate targets within the signaling cascade that USH3A is part of, thereby enhancing its role in sensory signal transduction. Similarly, the beta-adrenergic agonist Isoproterenol stimulates the same cyclic AMP-mediated pathway, potentially increasing USH3A activity. Phorbol 12-myristate 13-acetate (PMA) activates PKC, which phosphorylates substrates within the USH3A pathway, contributing to the enhancement of USH3A's sensory functions. The PDE5 inhibitors Sildenafil, Zaprinast, and Vardenafil, and the PDE4 inhibitor Rolipram, prevent the breakdown of cyclic nucleotides, augmenting signaling pathways that could potentiate the activity of USH3A in visual and auditory processes.
Furthermore, Ionomycin, by increasing intracellular calcium levels, may activate calcium-dependent proteins that interact with USH3A, thus enhancing its activity. Retinoic acid could modulate the expression of proteins that areinvolved with USH3A, indirectly increasing its functional activity. LY294002, by inhibiting PI3K, might alter intracellular signaling to favor pathways that enhance the activity of USH3A. Genistein's inhibition of tyrosine kinases may reduce competitive signaling and thus facilitate USH3A pathway activation. Collectively, these USH3A Activators work through different yet interconnected signaling pathways, from cAMP/PKA modulation, calcium signaling, to kinase inhibition, all converging on the enhancement of USH3A's sensory functions. They underscore the complex network of intracellular signals that govern the activity of USH3A, highlighting the potential for precise manipulation of its role in sensory systems without necessarily altering its expression levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases intracellular cAMP levels, which activates protein kinase A (PKA). PKA can then phosphorylate target proteins that are part of the signaling pathways USH3A is involved in, potentially enhancing USH3A's function in sensory cells. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentration, triggering calcium-signaling pathways. These pathways can lead to the activation of proteins that interact with or regulate USH3A, thus enhancing its activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid acts on retinoic acid receptors to modulate gene expression. Through this modulation, proteins that directly interact with USH3A might be upregulated, thereby enhancing the function of USH3A in visual and auditory processes. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can increase cAMP levels, similar to Forskolin, and activate PKA. This can enhance USH3A signaling pathways through PKA-mediated phosphorylation events. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate various substrates involved in signaling pathways that include USH3A, potentially enhancing USH3A's role in cellular signaling related to sensory functions. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits PDE5 and PDE9, which could lead to enhanced cGMP levels and subsequent activation of cGMP-dependent protein kinases that could potentiate USH3A function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits PDE4, resulting in increased cAMP levels. This elevation can activate cAMP-dependent signaling pathways, potentially enhancing the functional activity of USH3A in sensory signal transduction. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $516.00 $720.00 $16326.00 | 7 | |
Vardenafil is another PDE5 inhibitor that could enhance cGMP signaling pathways. This may indirectly enhance the function of USH3A, particularly in sensory cells. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
db-cAMP is a cell-permeable cAMP analog that directly elevates cAMP levels within cells, potentially enhancing USH3A activity through PKA-mediated signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that, by reducing competitive kinase signaling, could potentiate signaling pathways involving USH3A and thus enhance its function. | ||||||